Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 10.5% in the morning session after the company reported better-than-expected fourth-quarter results, highlighted by a smaller loss than ...
StockStory.org on MSN
10x Genomics (NASDAQ:TXG) delivers impressive Q4 CY2025
Biotech company 10x Genomics (NASDAQ:TXG) reported in Q4 CY2025, but sales were flat year on year at $166 million. The ...
Zacks Investment Research on MSN
10x Genomics (TXG) reports Q4 loss, beats revenue estimates
10x Genomics (TXG) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.4 per share a year ago. These figures are ...
An updated edition of the Nov. 18, 2025, article. Genomics is a broad and detailed study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this ...
Wave Life Sciences Ltd. (NASDAQ:WVE) is among the Best Genomics Stocks. TheFly reports that on December 19, 2025, H.C. Wainwright upgraded Wave Life Sciences Ltd. (NASDAQ:WVE)’s price target from $22 ...
Full-year instruments revenue fell 39% year-over-year while consumables grew 3%, highlighting a key challenge as the company navigates a strategic product transition. Wall Street expects a ...
The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund ...
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium provides a unique platform ...
On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer samples into high-resolution, multimodal datasets, backed by £18.9 million in ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, ...
Tempus AI, Inc. (NASDAQ:TEM) is among the Best Genomics Stocks. TheFly reported on December 22, 2025, that Canaccord reduced the price objective for Tempus AI, Inc. (NASDAQ:TEM) to $80 from $95. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results